US · OGN · DRUG MANUFACTURERS - GENERAL
Organon & Co. (OGN) intrinsic value and stock valuation
$13.89as of 2026-11-21 · Mkt cap 3.57B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Organon & Co. DCF and intrinsic value
InvestorsCraft values OGN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OGN’s statements →
Organon & Co. Graham Number
Graham Number: $6.85d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Guardian Pharmacy Services, Inc. (GRDN) $46.94
- Nuvation Bio Inc. (NUVB) $3.80
- Pediatrix Medical Group, Inc. (MD) $30.22
- Harmony Biosciences Holdings, Inc. (HRMY) $32.59
- Aurinia Pharmaceuticals Inc. (AUPH) $14.70
- Phibro Animal Health Corporation (PAHC) $33.29
- Alvotech (ALVO) $4.12
- Tilray Brands, Inc. (TLRY) $1.89
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.4B | $6.26B | $6.17B | $6.3B |
| Operating income | $1.29B | $1.49B | $1.33B | $1.71B | $1.92B |
| Net income | $187M | $864M | $1.02B | $917M | $1.35B |
| EPSd | $717.1K | $3.33M | $3.99M | $3.59M | $5.33M |
| Operating cash flow | $700M | $939M | $799M | $858M | $2.46B |
| Capital expenditure | -$-162M | -$-351M | -$-261M | -$-427M | -$-488M |
| Free cash flow | $538M | $588M | $538M | $431M | $1.97B |
| Total assets | $12.9B | $13.1B | $12.1B | $11B | $10.7B |
| Total debt | $8.8B | $9.04B | $8.93B | $9.11B | $9.36B |
| Net debt | $8.23B | $8.36B | $8.24B | $8.41B | $8.63B |
| Total equity | $752M | $472M | -$-70M | -$-892M | -$-1.51B |
| Cash and short-term investments | $574M | $675M | $693M | $706M | $737M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.4B | $6.26B | $6.17B | $6.3B |
| Cost of revenue | $2.85B | $2.69B | $2.52B | $2.29B | $2.38B |
| Gross profit | $3.36B | $3.72B | $3.75B | $3.88B | $3.92B |
| Research and development expenses | $366M | $469M | $528M | $471M | $443M |
| Selling, general and administrative expenses | $1.71B | $1.76B | $1.89B | $1.7B | $1.67B |
| Other expenses | $10M | $0.00 | $0.00 | $0.00 | -$-104M |
| Operating expenses | $2.09B | $2.23B | $2.42B | $2.18B | $2.01B |
| Cost and expenses | $4.93B | $4.92B | $4.94B | $4.47B | $4.39B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $504M | $520M | $527M | $422M | $258M |
| Depreciation and amortization | $353.3M | $277M | $236M | $212M | $195M |
| Ebitda | $1.28B | $1.6B | $1.44B | $1.76B | $1.98B |
| Operating income | $1.29B | $1.49B | $1.33B | $1.71B | $1.92B |
| Total other income/expenses, net | -$-860M | -$-679M | -$-654M | -$-583M | -$-386M |
| Income before tax | $425M | $807M | $673M | $1.12B | $1.53B |
| Income tax expense | $238M | -$-57M | -$-350M | $205M | $178M |
| Net income | $187M | $864M | $1.02B | $917M | $1.35B |
| Weighted average shares outstanding | $259.5M | $257.1M | $255.2M | $254.1M | $253.6M |
| Weighted average diluted shares outstanding | $260.8M | $259.2M | $256.3M | $255.2M | $253.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $574M | $675M | $693M | $706M | $737M |
| Net receivables | $1.43B | $1.49B | $1.86B | $1.61B | $1.51B |
| Inventory | $1.41B | $1.32B | $1.32B | $1B | $915M |
| Total current assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B |
| Property, plant and equipment, net | $1.3B | $1.33B | $1.36B | $1.23B | $1.2B |
| Goodwill and intangible assets | $5.28B | $6.09B | $5.14B | $5.25B | $5.25B |
| Long-term investments | $0.00 | $27M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $8.52B | $8.75B | $7.55B | $7.02B | $6.92B |
| Total assets | $12.9B | $13.1B | $12.1B | $11B | $10.7B |
| Accounts payable | $952M | $1.15B | $1.31B | $1.13B | $1.38B |
| Short-term debt | $56M | $64M | $55M | $57M | $55M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.39B | $2.72B | $2.92B | $2.51B | $2.6B |
| Long-term debt | $8.76B | $8.97B | $8.88B | $9.06B | $9.31B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $9.73B | $9.91B | $9.21B | $9.34B | $9.59B |
| Capital lease obligations | $116M | $112M | $125M | $150M | $184M |
| Total liabilities | $12.1B | $12.6B | $12.1B | $11.8B | $12.2B |
| Common stock | $3M | $3M | $3M | $3M | $3M |
| Retained earnings | $1.11B | $1.01B | $443M | -$-331M | -$-998M |
| Accumulated other comprehensive income (loss) | -$-527M | -$-649M | -$-541M | -$-564M | -$-513M |
| Total equity | $752M | $472M | -$-70M | -$-892M | -$-1.51B |
| Total investments | $0.00 | $27M | $0.00 | $0.00 | $0.00 |
| Total debt | $8.8B | $9.04B | $8.93B | $9.11B | $9.36B |
| Net debt | $8.23B | $8.36B | $8.24B | $8.41B | $8.63B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $187M | $864M | $1.02B | $917M | $1.35B |
| Depreciation and amortization | $361M | $277M | $236M | $212M | $195M |
| Stock-based compensation | $77M | $105M | $101M | $75M | $59M |
| Change in working capital | -$-247M | -$-278M | -$-155M | -$-452M | $702M |
| Accounts receivable | $79M | $383M | -$-212M | -$-123M | -$-277M |
| Inventory | -$-13M | -$-131M | -$-230M | -$-220M | -$-138M |
| Accounts payable | -$-217M | -$-157M | $163M | -$-237M | $663M |
| Net cash provided by operating activities | $700M | $939M | $799M | $858M | $2.46B |
| Investments in property, plant and equipment | -$-192M | -$-351M | -$-259M | -$-427M | -$-488M |
| Acquisitions, net | -$-198M | -$-166M | -$-2M | -$-124M | -$-185M |
| Net cash used for investing activities | -$-390M | -$-513M | -$-260M | -$-420M | -$-481M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-22M | -$-17M | $0.00 | $0.00 |
| Dividends paid | -$-88M | -$-297M | -$-294M | -$-290M | -$-145M |
| Net cash used for financing activities | -$-561M | -$-368M | -$-569M | -$-433M | -$-1.33B |
| Net change in cash | -$-101M | -$-18M | -$-13M | -$-31M | $667M |
| Cash at end of period | $574M | $675M | $693M | $706M | $737M |
| Operating cash flow | $700M | $939M | $799M | $858M | $2.46B |
| Capital expenditure | -$-162M | -$-351M | -$-261M | -$-427M | -$-488M |
| Free cash flow | $538M | $588M | $538M | $431M | $1.97B |
Line items
Line items
Line items
About Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
- CEO
- Joseph T. Morrissey Jr.
- Employees
- 10K
- Beta
- 1.54
Explore
Frequently asked questions
What is the intrinsic value of Organon & Co. (OGN)?
Organon & Co. (OGN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OGN undervalued?
OGN trades at a price of $13.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.